Abstract:STUDY QUESTIONWhat is the true incidence of chromosomal mosaicism in embryos analyzed by preimplantation genetic testing (PGT).SUMMARY ANSWERThe true incidence of chromosomal mosaicism is much lower than we usually surmise.WHAT IS KNOWN ALREADYIn recent years, contemporary methods for chromosome analysis, along with the biopsy of more than one cell, have given rise to an increased rate of chromosomal mosaicism detection after preimplantation genetic testing for aneuploidy. However, the exorbitant incidence of mosaicism represents a dilemma and imposes restrictions on the application of PGT treatment. Concern has been raised about the possibility that the incidence of chromosomal mosaicism is overestimated and quite a few of the results are false-positive errors. However, studies verifying the diagnosis of chromosomal mosaicism and assessing the true incidence of chromosomal mosaicism are limited.STUDY DESIGN, SIZE, DURATIONA total of 1719 blastocysts from 380 patients who underwent PGT treatment were retrospectively analyzed to evaluate the typical incidence of mosaicism. Then 101 embryos donated by 70 couples were re-biopsied and dissected into three portions if available: trophectoderm (TE), inner cell mass (ICM), and the remaining portions. All the portions were tested using next-generation sequencing (NGS), and the results were compared to the original diagnosis.PARTICIPANTS/MATERIALS, SETTING, METHODSThe setting for this study was a university-affiliated center with an in-house PGT laboratory. All samples were amplified with multiple annealing and looping-based amplification cycles (MALBACs) and the NGS was carried out on a Life Technologies Ion Proton platform.MAIN RESULTS AND THE ROLE OF CHANCEA clinical TE biopsy revealed an incidence of 11.9% for diploid-aneuploid mosaicism (DAM), 17.3% for aneuploid mosaicism (AM) and 29.1% in total. After rebiopsy, 94.1% whole-chromosome aneuploidies and 82.8% segmental-chromosome aneuploidies were confirmed in the embryos. As for the mosaic errors, only 32 (31.7%) out of 101 embryos presented with uniform chromosomal aberrations in agreement with the original biopsy results, 15 (14.8%) embryos presented with de novo chromosomal aberrations, and 54 (53.5%) embryos showed a euploid profile in all portions. Among the 32 uniform embryos, the true mosaicism was confirmed in only 4 cases, where a reciprocal chromosomal aberration was identified; 14 embryos presented with identical mosaicism, providing the moderate evidence for true mosaicism; and 14 embryos displayed uniform full aneuploidies in all portions of embryo, revealing a high-grade mosaicism or a false-negative diagnosis. Logistical regression analysis revealed that the concordance rate with ICM was associated with the type and level of mosaicism. The concordance rate of segmental-chromosome mosaicism was significantly lower than whole-chromosome mosaicism (adjusted Odds Ratio (aOR): 5.137 (1.061, 24.876), P = 0.042) and compared to DAM, the concordance rate of AM was significantly higher (aOR: 6.546 (1.354, 31.655), P = 0.019). The concordance rate also increased with increasing levels of mosaicism (P < 0.001).LIMITATIONS, REASONS FOR CAUTIONThis study was limited by a small sample size and the use of a single whole-genome amplification (WGA) method and NGS platform. These findings are only applicable to samples subjected to MALBAC amplification and Ion Proton platform, and studies involving larger sample sizes and multiple WGA methods and NGS platforms are required to prove our findings.WIDER IMPLICATIONS OF THE FINDINGSTE biopsy is reliable to detect whole-chromosome aneuploidies, but the ability to diagnose mosaicism is doubtful. More attention should be paid to false-positive and false-negative errors in NGS-based PGT, especially for laboratories using less stringent criteria for mosaicism classification (i.e. 20-80%), which might be subject to a much higher false-positive mosaicism rate in the practice.STUDY FUNDING/COMPETING INTEREST(S)This study was supported by grants from the National Key R&D Program of China (No. 2016YFC1000206-5) and the National Natural Science Foundation of China (No. 81701509).TRIAL REGISTRATION NUMBERN/A.

42. RETROSPECTIVE PGT-A ANALYSIS FOR MULTIPLE DISPLACEMENT AMPLIFICATION (MDA) PRODUCTS OF EMBRYOS CORRESPONDING TO 21 SPONTANEOUS ABORTIONS BY NGS

34. RETROSPECTIVE PGT-A ANALYSIS FOR MULTIPLE DISPLACEMENT AMPLIFICATION PRODUCTS OF EMBRYOS CORRESPONDING TO 104 LIVE BIRTHS BY NEXT-GENERATION SEQUENCING (NGS)

Application of Preimplantation Genetic Testing for Aneuploidies with Next-Generation Sequencing in Women with Advanced Maternal Age

Aneuploidy Rates and Clinical Pregnancy Outcomes after Preimplantation Genetic Testing for Aneuploidy Using the Progestin-Primed Ovarian Stimulation Protocol or the Gonadotropin-Releasing Hormone Antagonist Protocol

Evaluating the Application Value of NGS-based PGT-A by Screening Cryopreserved MDA Products of Embryos from PGT-M Cycles with Known Transfer Outcomes

Comparison of Chromosomal Status in Reserved Multiple Displacement Amplification Products of Embryos That Resulted in Miscarriages or Live Births: a Blinded, Nonselection Case–control Study

Effects of PGT-A on Pregnancy Outcomes for Young Women Having One Previous Miscarriage with Genetically Abnormal Products of Conception

A Series of 23 Cases

61. PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISEASE OF SPINAL MUSCULAR ATROPHY BY MULTIPLE DISPLACEMENT AMPLIFICATION: 11 UNAFFECTED LIVEBIRTHS

[Analysis of related factors influencing the detection rate of mosaic embryo and the pregnancy outcomes with mosaic embryo transfers]

Genetic screening revealed widespread mosaicism in human early embryos

Healthy Live Births after the Transfer of Mosaic Embryos: Self-Correction or PGT-A Overestimation?

Preimplantation Genetic Testing for Monogenic Disease of Spinal Muscular Atrophy by Multiple Displacement Amplification: 11 Unaffected Livebirths

Human embryos harbor complex mosaicism with broad presence of aneuploid cells during early development

Blastocyst Formation Rates in Chromosomally Normal Versus Abnormal Embryos As Analyzed by 24 Chromosome Microarray-Based Anueploidy Screening (Mpgd)

The True Incidence of Chromosomal Mosaicism after Preimplantation Genetic Testing is Much Lower Than That Indicated by Trophectoderm Biopsy.

The aneuploidy testing of blastocysts developing from 0PN and 1PN zygotes in conventional IVF through TE-biopsy PGT-A and minimally invasive PGT-A

Impact of preimplantation genetic testing for aneuploidies (PGT-A) on first trimester biochemical markers – PAPP-A (placenta-associated plasma protein) and free β-hCG (human chorionic gonadotropin)

Genome-wide haplotyping embryos developing from 0PN and 1PN zygotes increases transferrable embryos in PGT-M

The inconsistency between two major aneuploidy-screening platforms—single-nucleotide polymorphism array and next-generation sequencing—in the detection of embryo mosaicism